You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
邁博藥業-B(02181.HK)與科興生物製藥就CMAB008訂立獨家許可協議
格隆匯 06-29 22:47

格隆匯6月29日丨邁博藥業-B(02181.HK)公吿,於2021年6月28日,公司間接全資附屬公司泰州邁博太科藥業有限公司("泰州藥業")與科興生物製藥股份有限公司("科興生物製藥")(上海證券交易所科創板上市公司(股份代號:688136))訂立獨家許可協議,據此,泰州藥業已向科興生物製藥授出有關於除中國大陸、日、歐洲及北美以外的所有國家及地區("合作區域")開發及商業化CMAB008的獨家許可。

各合作區域的獨家許可的期限單獨計算,且應自CMAB008於該相關合作區域獲批上市日期起計不少於十年(可自動再延長十年)。泰州藥業與科興生物製藥已就北美地區以外的美洲國家和地區銷售目標進行約定:第一個和第二個完整銷售年度合計銷售目標為不低於二十萬支;第三個完整銷售年度起,年度銷售目標為不低於二十萬支╱年。

CMAB008為一種重組抗TNF-alpha嵌合單克隆抗體,是用於治療類風濕關節炎、成人及兒童克羅恩病、瘻管性克羅恩病、強直性脊柱炎、銀屑病及成人潰瘍性結腸炎的英夫利西單抗生物類似藥,及集團的核心產品之一。

科興生物製藥是一家主要從事重組蛋白藥物和微生態製劑的研發、生產、銷售一體化的創新型生物製藥企業,專注於抗病毒、腫瘤與免疫、血液、消化以及退行性疾病等治療領域的藥物研發。 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account